Plain-English translation of NCT06277427 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Read our Lupus Nephritis research guide βThis study doesn't follow the usual testing phases β it may be an observational study or a different type of research.
This trial is testing a new therapy called PRG-1801, which uses special immune cells designed in the laboratory to target and eliminate the cells causing severe lupus kidney disease or blood vessel inflammation. The therapy is for patients whose disease has not improved with standard medicines. Researchers want to learn if this new treatment is safe and effective.
Some patients with lupus kidney disease or blood vessel inflammation do not get better with standard treatments, and their conditions can be life-threatening. This medication is designed to attack the root cause of these diseases by eliminating specific antibody-producing cells that fuel the inflammation.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
If you qualify, doctors will first collect your white blood cells through a procedure similar to donating blood plasma. These cells will be sent to a laboratory where they are engineered into the new therapy. You will then receive medication to clear certain lymphocytes from your body, followed by an infusion of the engineered cells. You will be monitored closely for at least 14 days after treatment, and the study team will follow your progress to track safety and whether the treatment helps your disease improve. The trial is enrolling 12 to 24 patients total across two different dose levels.
AI-generated summary from trial data Β· Jun 5, 2026 Β· Not medical advice
China